Inflammatory Mechanisms of HCC Development

Basit Öğe Kaydı
dc.authoridD'Alessandro, Rosalba/0000-0001-9604-366X
dc.authoridGUERRA, Vito/0000-0001-7827-1909
dc.authoridmessa, Caterina/0000-0003-1734-0039
dc.authorwosidD'Alessandro, Rosalba/J-2351-2018
dc.contributor.authorRefolo, Maria Grazia
dc.contributor.authorMessa, Caterina
dc.contributor.authorGuerra, Vito
dc.contributor.authorCarr, Brian Irving
dc.contributor.authorD'Alessandro, Rosalba
dc.date.accessioned2024-08-04T20:47:13Z
dc.date.available2024-08-04T20:47:13Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHCC (hepatocellular carcinoma) is the second leading cause of cancer deaths worldwide, with several etiologic causes, mostly inflammation-associated. Different inflammatory responses in the liver can be triggered by different etiological agents. The inflammatory process can be resolved or be persistent, depending on the etiology and multiple other factors. Chronic inflammation, tissue remodeling, genetic alterations, and modifications in cellular signaling are considered to be key processes promoting immunosuppression. The progressive immunosuppression leads to the inactivation of anti-tumor immunity involved in HCC carcinogenesis and progression. Tumor cellular processes including DNA damage, necrosis, and ER (endoplasmic reticulum) stress can affect both immune-surveillance and cancer-promoting inflammation, supporting a mutual interdependence. Here, we review the current understanding of how chronic liver injury and inflammation is triggered and sustained, and how inflammation is linked to HCC. The identification of many hepatic microenvironmental inflammatory processes and their effector molecules, has resulted in extensive translational work and promising clinical trials of new immunomodulatory agents.en_US
dc.description.sponsorshipITALIAN MINISTRY OF PUBLIC HEALTH [6/2016]en_US
dc.description.sponsorshipThis research was funded by ITALIAN MINISTRY OF PUBLIC HEALTH, grant number 6/2016.en_US
dc.identifier.doi10.3390/cancers12030641
dc.identifier.issn2072-6694
dc.identifier.issue3en_US
dc.identifier.pmid32164265en_US
dc.identifier.scopus2-s2.0-85082311225en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/cancers12030641
dc.identifier.urihttps://hdl.handle.net/11616/99234
dc.identifier.volume12en_US
dc.identifier.wosWOS:000530232300117en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcancer etiologyen_US
dc.subjectchronic inflammationen_US
dc.subjectimmunosurveillanceen_US
dc.subjectimmunosuppressionen_US
dc.subjectHCCen_US
dc.titleInflammatory Mechanisms of HCC Developmenten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu